ストックスクリーナーアプリを入手
6.48
2.69%
0.17
プレマーケット:
6.39
-0.09
-1.39%
前日終値:
$6.31
開ける：
$6.45
24時間の取引高:
244.76K
Relative Volume:
1.10
時価総額：
$411.50M
収益：
-
当期純損益:
$-106.47M
株価収益率:
-3.3605
EPS:
-1.9283
ネットキャッシュフロー:
$-88.80M
1週間 パフォーマンス:
-1.52%
1か月 パフォーマンス:
+7.64%
6か月 パフォーマンス:
+10.20%
1年 パフォーマンス:
-8.47%
1日の値動き範囲:
$6.2932
$6.69
1週間の範囲:
$6.20
$6.77
52週間の値動き範囲:
$4.345
$7.4799
Aura Biosciences Inc Stock (AURA) Company Profile
Compare AURA vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
6.48 | 400.71M | 0 | -106.47M | -88.80M | -1.9283 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-26 | 再開されました | Evercore ISI | Outperform |
| 2025-05-28 | 再開されました | H.C. Wainwright | Buy |
| 2024-07-25 | 開始されました | H.C. Wainwright | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-04-17 | 再開されました | BTIG Research | Buy |
| 2022-07-19 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Aura Biosciences Inc (AURA) 最新ニュース
What makes Aura Biosciences (AURA) a new buy stock - MSN
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Bear Alert: Is Aura Biosciences Inc stock undervalued right nowMarket Weekly Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Aura Biosciences (AURA) to Release Earnings on Monday - MarketBeat
Aura Biosciences Posts Q2 Cash Surge - AOL.com
Aura Biosciences Eyes Phase 3 Enrollment Milestone, Reaffirms Q4 2027 Melanoma Data Timeline - Yahoo Finance
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Sahm
AURA: Phase 3 ocular oncology drug nears enrollment completion, with pivotal data expected in Q4 2027 - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Aug Sectors: Is Aura Biosciences Inc stock undervalued right now2025 Investor Takeaways & Reliable Price Breakout Signals - baoquankhu1.vn
Why (AURA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference - MarketBeat
AURA: Late-stage oncology programs show strong safety, efficacy, and market potential, with key data ahead - TradingView
Aura's Bel-sar — One Asset, Multiple Oncology Opportunities - RTTNews
Is Assertio (ASRT) Surpassing Other Healthcare Stocks in Performance This Year? - Bitget
Aura Biosciences (AURA) officer granted RSUs and 112,661-share option - Stock Titan
Aura Biosciences (AURA) officer receives RSU and option grants - Stock Titan
Large equity awards to Elisabet de los Pinos at Aura Biosciences (AURA) - Stock Titan
Aura Biosciences (AURA) CTO receives new stock option and RSU awards - Stock Titan
Aura Biosciences (AURA) grants stock options and RSUs to its CMO - Stock Titan
Aura Biosciences (AURA) SVP awarded 80,472 options and 44,528 RSUs - Stock Titan
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Wall Street Recap: Is Aura Biosciences Inc in a long term uptrend2025 Technical Overview & Risk Managed Investment Strategies - baoquankhu1.vn
Aura Biosciences, Inc. (AURA) Stock Analysis: A Biotech Gem With 235% Potential Upside - DirectorsTalk Interviews
AURA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
Aura Biosciences plans fireside chats at three March healthcare events - Stock Titan
Update Recap: Is Aura Biosciences Inc stock undervalued right now2025 Pullback Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Understanding Momentum Shifts in (AURA) - Stock Traders Daily
Aura Biosciences, Inc. (AURA) Stock Analysis: Assessing a Potential 300% Upside in Biotech Innovation - DirectorsTalk Interviews
Aura Biosciences Expands Evidence With New Patient-Reported Outcome Study in Eye Cancer - TipRanks
Ocular melanoma Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Delcath System, Aura Biosciences, Seagen, IDEAYA, Ascentage Pharma - Barchart.com
Form 4: Kilroy Conor reports sale transactions in AURA - Stock Titan
Are Medical Stocks Lagging Assertio (ASRT) This Year? - Bitget
Can Aura Biosciences Inc. outperform under higher oil prices2025 Investor Takeaways & Growth Focused Entry Point Reports - mfd.ru
Is Aura Biosciences Inc. exposed to currency risksBreakout Watch & Growth Oriented Trade Recommendations - mfd.ru
What Makes Aura Biosciences (AURA) a New Buy Stock - Yahoo Finance
Aura Biosciences, Inc. (AURA) Stock Analysis: Unpacking a 259% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Aug Big Picture: Can Aura Biosciences Inc benefit from deglobalizationQuarterly Earnings Summary & AI Driven Stock Price Forecasts - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (AURA) Movement - Stock Traders Daily
Should you buy the dip on Aura Biosciences Inc.2025 Valuation Update & Weekly High Conviction Ideas - mfd.ru
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aura Biosciences, Inc. (AURA) Stock Analysis: A Biotech Player with a Potential Upside of 237% - DirectorsTalk Interviews
AURA Should I Buy - Intellectia AI
Discipline and Rules-Based Execution in AURA Response - Stock Traders Daily
Guidance Update: Can Aura Biosciences Inc deliver alphaTrade Entry Report & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Aura Biosciences, Inc. (AURA): Investor Outlook with a Remarkable 257.93% Potential Upside - DirectorsTalk Interviews
Following a 29% decline over last year, recent gains may please Aura Biosciences, Inc. (NASDAQ:AURA) institutional owners - simplywall.st
Aura Biosciences Inc (AURA) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):